



5.70.083

Section:	Prescription Drugs	Effective Date:	October 1, 2023
Subsection:	Analgesics and Anesthetics	Original Policy Date:	September 18, 2020
Subject:	Olinvyk	Page:	1 of 7

Last Review Date: September 8, 2023

Olinvyk

Description

Olinvyk (olicecidine) injection

Background

Olinvyk (olicecidine) is a full opioid agonist and is relatively selective for the mu-opioid receptor. The principal therapeutic action of Olinvyk is analgesia, although the precise mechanism of action is unknown. Like all full opioid agonists, there is no ceiling effect to analgesia for Olinvyk. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory, and CNS depression (1).

Regulatory Status

FDA-approved indication: Olinvyk is an opioid agonist indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate (1).

Limitations of Use:

Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, reserve Olinvyk for use in patients for whom alternative treatment options: (1)

- Have not been tolerated, or are not expected to be tolerated.
- Have not provided adequate analgesia, or are not expected to provide adequate analgesia.

Olinvyk has boxed warnings for the following (1):

5.70.083

Section:	Prescription Drugs	Effective Date:	October 1, 2023
Subsection:	Analgesics and Anesthetics	Original Policy Date:	September 18, 2020
Subject:	Olinvyk	Page:	2 of 7

- Olinvyk exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Patient risk should be assessed before prescribing, and patients should be monitored regularly for the development of behaviors or conditions.
- Serious, life-threatening, or fatal respiratory depression may occur. Patients should be monitored for respiratory depression, especially during initiation or following a dose increase.
- Prolonged use of Olinvyk during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated.
- Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Concomitant prescribing should be reserved for use in patients for whom alternative treatment options are inadequate. Dosages and durations should be limited to the minimum required and patient should be followed for signs and symptoms of respiratory depression and sedation.

Olinvyk is for intravenous administration only. The cumulative total daily dose should not exceed 27 mg, as total daily doses greater than 27 mg may increase the risk for QTc interval prolongation. Olinvyk 30 mg/30 mL (1mg/mL) vial is intended for patient-controlled analgesia (PCA) use only. Use of Olinvyk beyond 48 hours has not been studied in controlled clinical trials (1).

The CDC guidelines find that concurrent use of benzodiazepines and opioids might put patients at greater risk for potentially fatal overdose. Three studies of fatal overdose deaths found evidence of concurrent benzodiazepine use in 31%–61% of decedents (2).

Olinvyk is contraindicated for use in patients: with significant respiratory depression; whom have bronchial asthma (acute and severe) in a setting that is unmonitored or in the absence of resuscitative equipment; or with known or suspected gastrointestinal obstructions, including paralytic ileus (1).

Avoid the use of mixed agonist/antagonist (e.g., pentazocine, nalbuphine, and butorphanol) or partial agonist (e.g., buprenorphine) analgesics in patients who are receiving Olinvyk. In these patients, mixed agonist/antagonist and partial agonist analgesics may reduce the analgesic effect and/or precipitate withdrawal symptoms (1).

Section:	Prescription Drugs	Effective Date:	October 1, 2023
Subsection:	Analgesics and Anesthetics	Original Policy Date:	September 18, 2020
Subject:	Olinvyk	Page:	3 of 7

The safety and effectiveness of Olinvyk in pediatric patients have not been established (1).

Related policies

Dsuvia, Opioid Injectables

Policy

This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.

Olinvyk may be considered **medically necessary** if the conditions indicated below are met.

Olinvyk may be considered **investigational** for all other indications.

Prior-Approval Requirements

Age 18 years of age or older

Diagnosis

Patients must have the following:

Severe acute pain

AND ALL of the following:

1. Alternative treatment options have been ineffective, not tolerated or inadequate for controlling the pain
 - a. These include: non-opioid analgesics and other treatment modalities
2. Prescriber agrees to assess patient for signs and symptoms of serotonin syndrome
3. Prescriber agrees to participate in the Opioid Analgesic REMS program and to monitor for abuse, misuse, addiction, and overdose and discontinue if necessary
(<https://opioidanalgesicrems.com>)
4. **NO** other opioid at prior authorization limits
5. **NO** dual therapy with opioid addiction treatment or methadone
6. **NO** dual therapy with mixed agonist/antagonist opioids (e.g.,

Section:	Prescription Drugs	Effective Date:	October 1, 2023
Subsection:	Analgesics and Anesthetics	Original Policy Date:	September 18, 2020
Subject:	Olinvyk	Page:	4 of 7

pentazocine, nalbuphine, and butorphanol) or partial agonist opioids (e.g., buprenorphine)

7. **NO** dual therapy with anti-anxiety benzodiazepine(s)
 - a. Alprazolam (Xanax)
 - b. Clonazepam (Klonopin)
 - c. Diazepam (Valium)
 - d. Lorazepam (Ativan)
 - e. Oxazepam (Serax)
 - f. Chlordiazepoxide (Librium)
 - g. Clorazepate dipotassium (Tranxene)
8. Prescriber will not exceed the FDA labeled dose of 27mg per day
9. Treatment duration will be limited to 48 hours

Prior – Approval *Renewal* Requirements

Same as above

Policy Guidelines

Pre - PA Allowance

None

Prior - Approval Limits

Quantity

Strength	Quantity for 2 Treatment Cycles*
1 mg/1 mL	108 vials OR
2 mg/2 mL	56 vials OR
30 mg/30 mL (for PCA only)	4 vials

*Maximum of 2 treatment cycles per year

Duration 365 days

Prior – Approval *Renewal* Limits

Same as above

Rationale

Olinvyk (olicecidine) is a full opioid agonist and is relatively selective for the mu-opioid receptor. The principal therapeutic action of Olinvyk is analgesia. Like all full opioid agonists, there is no

5.70.083

Section:	Prescription Drugs	Effective Date:	October 1, 2023
Subsection:	Analgesics and Anesthetics	Original Policy Date:	September 18, 2020
Subject:	Olinvyk	Page:	5 of 7

ceiling effect to analgesia for Olinvyk. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory, and CNS depression. Additionally, use of Olinvyk beyond 48 hours has not been studied in controlled clinical trials (1).

Prior authorization is required to ensure the safe, clinically appropriate, and cost-effective use of Olinvyk while maintaining optimal therapeutic outcomes.

References

1. Olinvyk [package insert]. Chesterbrook, PA: Trevena, Inc.; July 2021.
2. Dowell D, Haegerich T, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain. CDC Guidelines 2016.

Policy History

Date	Action
September 2020	Addition to PA
December 2020	Annual review
June 2021	Annual review and reference update. Addition of requirement for no dual therapy with mixed agonist/antagonist opioids or partial agonist opioids per SME
September 2022	Annual review and reference update
September 2023	Annual review

Keywords

This policy was approved by the FEP[®] Pharmacy and Medical Policy Committee on September 8, 2023 and is effective on October 1, 2023.

Section:	Prescription Drugs	Effective Date:	October 1, 2023
Subsection:	Analgesics and Anesthetics	Original Policy Date:	September 18, 2020
Subject:	Olinvyk	Page:	6 of 7

Appendix 1 - List of Serotonergic Medications

Selective Serotonin Reuptake Inhibitors (SSRIs)

paroxetine	Paxil, Paxil CR, Pexeva, Brisdelle
fluvoxamine	Luvox, Luvox CR
fluoxetine	Prozac, Prozac Weekly, Sarafem, Selfemra, Symbyax
sertraline	Zoloft
citalopram	Celexa
escitalopram	Lexapro

Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)

venlafaxine	Effexor XR
desvenlafaxine	Pristiq, Khedezla
duloxetine	Cymbalta
milnacipran	Savella

Tricyclic Antidepressants (TCAs)

amitriptyline	No brand name currently marketed
desipramine	Norpramin
clomipramine	Anafranil
imipramine	Tofranil, Tofranil PM
nortriptyline	Pamelor, Aventyl
protriptyline	Vivactil
doxepin	Zonalon, Silenor
trimipramine	Surmontil

Monoamine Oxidase Inhibitors (MAOIs)

isocarboxazid	Marplan
phenelzine	Nardil
selegiline	Emsam, Eldepryl, Zelapar
tranylcypromine	Parnate

Section:	Prescription Drugs	Effective Date:	October 1, 2023
Subsection:	Analgesics and Anesthetics	Original Policy Date:	September 18, 2020
Subject:	Olinvyk	Page:	7 of 7

Other Psychiatric Medicines

amoxapine	No brand name currently marketed
maprotiline	No brand name currently marketed
nefazodone	No brand name currently marketed
trazodone	Oleptro
bupirone	No brand name currently marketed
vilazodone	Viibryd
mirtazapine	Remeron, Remeron Soltab
lithium	Lithobid

Migraine Medicines

almotriptan	Axert
frovatriptan	Frova
naratriptan	Amerge
rizatriptan	Maxalt, Maxalt-MLT
sumatriptan	Imitrex, Imitrex Statdose, Alsuma, Sumavel Dosepro, Zecuity, Treximet
zolmitriptan	Zomig, Zomig-ZMT

Antiemetics

ondansetron	Zofran, Zofran ODT, Zuplenz
granisetron	Kytril, Sancuso
dolasetron	Anzemet
palonosetron	Aloxi

Other Serotonergic Medicines

dextromethorphan	Bromfed-DM, Delsym, Mucinex DM, Nuedexta
linezolid	Zyvox
cyclobenzaprine	Amrix
methylene blue	
St. John's wort	
tryptophan	